acipimox

Phase 2Small molecule

Boehringer Ingelheim

acipimox is one of 140 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

139

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseUnknown

HyperlipidemiaActive, not recruiting

ArteriosclerosisUnknown

Prediabetes SyndromeActive, not recruiting

MetabolismCompleted

MitochondriaCompleted

GrowthEnrolling by invitation

Cardiovascular DiseasePreclinical

Unknown

HyperlipidemiaPreclinical

Active, not recruiting

ArteriosclerosisPreclinical

Unknown

Prediabetes SyndromePreclinical

Active, not recruiting

MetabolismPreclinical

Completed

MitochondriaPreclinical

Completed

GrowthPhase 2

Enrolling by invitation

Competition

Competitive Landscape

147 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Cardene

Sun Pharmaceutical Industries, Inc.

Primacor

Geodon

Giapreza

LLa Jolla Pharmaceutical Company

Approved

—5

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Midamor

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Colcrys

1 9

Pelacarsen

Novartis

Phase 3

1 10

Cagrilintide

Novo Nordisk

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Study completion

NCT06229678

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes

Completed·MMedical University of Vienna·Phase 2/3·NCT01980524·8 enrolled

Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes

Completed·UUniversity of Colorado, Denver·N/A·NCT01580813·13 enrolled

Lip2 trials

Lipolytic Effects of GH in Hypopituitary Patients in Vivo

Completed·UUniversity of Aarhus·N/A·NCT02782208·9 enrolled

The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin

Completed·UUniversity of Aarhus·N/A·NCT01209416·8 enrolled

Heart Failure2 trials

Metabolic Modulation as Treatment in Acute Heart Failure

Terminated·UUniversity of Aarhus·Phase 2·NCT00449423·32 enrolled

Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure

Completed·UUniversity of Aarhus·N/A·NCT00549614·28 enrolled

Hyperlipidemia1 trial

Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT00246402·30 enrolled

Mitochondria1 trial

Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function

Completed·MMaastricht University Medical Center·N/A·NCT00943059·31 enrolled

10 more indications

Metabolic Syndrome1 trial

The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

Completed·—·Phase 2/3·NCT00759291·40 enrolled

Vascular Function1 trial

Free Fatty Acids and Vascular Function in Subjects With Diabetes

Completed·—·Phase 1/2·NCT00153179·40 enrolled

PreDiabetes1 trial

Glucose and Glycogen Dynamics in Prediabetes

Recruiting·MMaastricht University Medical Center··NCT06317142·45 enrolled

Type 1 Diabetes1 trial

Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes

Completed·UUniversity of Colorado, Denver·Phase 3·NCT01816165·28 enrolled

Obesity1 trial

Effects of Acipimox on Mitochondrial Function in Obesity

Completed·MMassachusetts General Hospital·Phase 2·NCT01488409·39 enrolled

Metabolism1 trial

Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise

Completed·UUniversity of Aarhus·N/A·NCT01260376·9 enrolled

Growth1 trial

Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia

Enrolling by invitation·—·Phase 2·NCT03338387·24 enrolled

Propranolol1 trial

In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02256722·12 enrolled

Exercise1 trial

Can the Health Benefits of a Walking-based Exercise Programme be Enhanced by Co-ingestion of a Lipid-lowering Drug?

Completed·LLiverpool John Moores University·N/A·NCT03809793·15 enrolled

Unspecified2 trials

The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion

Completed·UUniversity of Aarhus·N/A·NCT02796950·8 enrolled

Ketones, SGLT2, HFrEF

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT06229678·71 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for acipimox. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — acipimox compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for acipimox. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Boehringer Ingelheim

acipimox

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Type 2 Diabetes2 trials

Lip2 trials

Heart Failure2 trials

Hyperlipidemia1 trial

Mitochondria1 trial

Metabolic Syndrome1 trial

Vascular Function1 trial

PreDiabetes1 trial

Type 1 Diabetes1 trial

Obesity1 trial

Metabolism1 trial

Growth1 trial

Propranolol1 trial

Exercise1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News